211 related articles for article (PubMed ID: 27515333)
1. 1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.
Piccolo R; Eitel I; Galasso G; Dominguez-Rodriguez A; Iversen AZ; Abreu-Gonzalez P; Windecker S; Thiele H; Piscione F
J Am Coll Cardiol; 2016 Aug; 68(7):727-38. PubMed ID: 27515333
[TBL] [Abstract][Full Text] [Related]
2. Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction.
Piccolo R; Galasso G; Eitel I; Dominguez-Rodriguez A; Iversen AZ; Gu YL; Abreu-Gonzalez P; de Smet BJ; Esposito G; Windecker S; Thiele H; Piscione F
Am J Cardiol; 2016 Dec; 118(12):1798-1804. PubMed ID: 27756477
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Piccolo R; Eitel I; Galasso G; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
Vascul Pharmacol; 2015 Oct; 73():32-7. PubMed ID: 26071862
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
5. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
6. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
7. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
[TBL] [Abstract][Full Text] [Related]
8. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
10. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
Stone GW; Maehara A; Witzenbichler B; Godlewski J; Parise H; Dambrink JH; Ochala A; Carlton TW; Cristea E; Wolff SD; Brener SJ; Chowdhary S; El-Omar M; Neunteufl T; Metzger DC; Karwoski T; Dizon JM; Mehran R; Gibson CM;
JAMA; 2012 May; 307(17):1817-26. PubMed ID: 22447888
[TBL] [Abstract][Full Text] [Related]
11. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
De Luca G; Verdoia M; Suryapranata H
Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
[TBL] [Abstract][Full Text] [Related]
12. Effects of baseline coronary occlusion and diabetes mellitus in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Piccolo R; Galasso G; Iversen AZ; Eitel I; Dominguez-Rodriguez A; Gu YL; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Trimarco B; Thiele H; Piscione F
Am J Cardiol; 2014 Oct; 114(8):1145-50. PubMed ID: 25193670
[TBL] [Abstract][Full Text] [Related]
13. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
14. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial.
Brener SJ; Maehara A; Dizon JM; Fahy M; Witzenbichler B; Parise H; El-Omar M; Dambrink JH; Mehran R; Oldroyd K; Gibson CM; Stone GW
JACC Cardiovasc Interv; 2013 Jul; 6(7):718-24. PubMed ID: 23866184
[TBL] [Abstract][Full Text] [Related]
15. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
16. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
[TBL] [Abstract][Full Text] [Related]
17. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
[TBL] [Abstract][Full Text] [Related]
18. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
20. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]